Valion Bio, Inc. (VBIO) Form 8-K — Nov 2, 2026
Valion Bio's 8-K discloses the termination of General Counsel Melinda Lackey effective October 30, 2026, with a Separation Agreement providing a gross severance of $26,750 plus COBRA premiums through November 30, 2026. More significantly, the filing announces that the Armed Forces Radiobiology Research Institute will evaluate the therapeutic efficacy of Valion's lead biologic Entolimod in gastrointestinal acute radiation syndrome, in a study fully funded by NIAID's Radiation and Nuclear Countermeasures Program.
Key figures
- Dose timing
- 24 hours after radiation exposure
- Cobra coverage end
- November 30, 2026
- Severance gross usd
- 26750
- Study topline timing
- early December 2026
- Monitoring period days
- 30
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.